Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pBI-4 Vaccine
- Development stage
- Phase 2
- Lead developer
- PapiVax Biotech
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
pBI-4 Vaccine is an investigational therapeutic DNA plasmid vaccine developed by PapiVax Biotech and Chang Gung Memorial Hospital for the treatment of human papillomavirus type 16 (HPV16)-positive cervical intraepithelial neoplasia (CIN) and persistent HPV16 infections. The vaccine is designed to express the HPV16 E6 and E7 oncoproteins, thereby inducing a robust, antigen-specific T-cell-mediated immune response to target and eliminate virally infected and precancerous cervical cells. To enhance cellular uptake and immunogenicity, the vaccine is administered intramuscularly via electroporation using the TriGrid Delivery System (as part of the PVX4 combination product). It is currently being evaluated in Phase II clinical trials.
- Other names
- pBI-4 DNA vaccinepBI4 DNA vaccinepBI 4 DNA vaccinepBI-4 plasmidpBI4 plasmidpBI 4 plasmidpBI-4 therapeutic DNA vaccinepBI4 therapeutic DNA vaccinepBI 4 therapeutic DNA vaccine
02
Targets
CALR (Calreticulin)MHC I (MHC class I})γδ TCR (T-cell receptor)HPV16 E6 oncoproteinHPV16 E7 (Human papillomavirus 16 E7 protein)
Beyond the preview
Go deeper on pBI-4 Vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pBI-4 Vaccine.